Drugs & Therapy Perspectives

, Volume 28, Issue 9, pp 1–4

Ulipristal acetate: a guide to its use in uterine fibroids

Authors

  • Jamie D. Croxtall
    • Adis
Adis Drug Clinical Q&A

DOI: 10.1007/BF03262118

Cite this article as:
Lyseng-Williamson, K.A. & Croxtall, J.D. Drugs Ther Perspect (2012) 28: 1. doi:10.1007/BF03262118
  • 58 Views

Abstract

Oral ulipristal acetate (Esmya™), a selective progesterone-receptor modulator, is an effective and well tolerated option for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. It is associated with rapid control of excessive uterine bleeding and sustained reductions in uterine fibroid volume.

Copyright information

© Springer International Publishing AG 2012